Group 1 - The overall performance of the pharmaceutical industry is weak, with an average revenue growth of 1.6% and a decline in average net profit by 3.2% for the first half of 2025 compared to the full year of 2024 [2] - The industry is expected to take time for performance improvement, with ongoing support policies for innovative drugs and devices, as well as improvements in global biopharmaceutical financing driving recovery [2] - A significant drop in stock prices was observed among innovative drug concept stocks in the Hong Kong market, with Huaneng Pharmaceutical down nearly 15% and Kelun-Bio down over 12% [4] Group 2 - The report by CMB International analyzed the performance of 393 pharmaceutical companies listed in A-shares and Hong Kong stocks, indicating a deterioration in both revenue and profit compared to the previous year [2] - The domestic centralized procurement policy optimization and continuous support for innovative drugs and devices are seen as crucial for the industry's recovery [2] - The stock performance of various pharmaceutical companies reflects the overall market sentiment, with multiple companies experiencing declines exceeding 9% [4]

Core Viewpoint - The report emphasizes the sustained high growth in the innovative pharmaceutical and medical device sectors, recommending continued investment in these areas [1]. Investment Highlights - The report maintains a recommendation for innovative pharmaceuticals and medical devices, highlighting the potential for value re-evaluation in the Pharma sector, with specific buy ratings for companies such as 恒瑞医药, 翰森制药, 三生制药, and 华东医药 [2]. - It continues to recommend Biopharma/Biotech companies that are gradually realizing their innovative pipelines and entering a performance growth phase, with buy ratings for 科伦博泰生物, 信达生物, 康方生物, 新诺威, 映恩生物, 京新药业, 微芯生物, 特宝生物, 我武生物, and 来凯医药 [2]. - The report also suggests investment in CXO and upstream pharmaceutical companies benefiting from innovation and recovery, maintaining buy ratings for 百普赛斯, 药明康德, 药明合联, 泰格医药, and 美诺华 [2]. - It recommends leading medical device companies expected to recover, with buy ratings for 微创医疗, 联影医疗, and 惠泰医疗 [2]. Market Performance - In the first week of September 2025, the A-share pharmaceutical sector outperformed the broader market, with the SW pharmaceutical and biotech index rising by 1.4% while the Shanghai Composite Index fell by 1.2% [3]. - Within the biopharmaceutical sector, the chemical preparations segment saw a notable increase of 4.5%, while biological products and medical services rose by 1.9% and 1.7%, respectively [3]. - The top-performing stocks included 海辰药业 (+28.7%), 长春高新 (+24.2%), and 百花医药 (+21.3%), while the worst performers were 舒泰神 (-24.0%), 广生堂 (-15.8%), and 塞力医疗 (-15.6%) [3]. - In the Hong Kong market, the healthcare sector also outperformed, with the Hang Seng Healthcare index rising by 7.0% and the biotech index by 7.3%, compared to a 1.4% increase in the Hang Seng Index [3]. - The top gainers in the Hong Kong market were 三叶草生物-B (+99%), 圣诺医药-B (+62%), and 加科思-B (+41%), while the biggest losers included 美中嘉和 (-11%), 科笛-B (-9%), and 思路迪医药股份 (-6%) [3]. - In the US market, the healthcare sector performed in line with the broader market, with the S&P Healthcare Select Sector Index increasing by 0.3%, matching the S&P 500's performance [4]. - The top gainers in the US healthcare sector included 德康医疗 (+7%), 生物基因 (+6%), and 环球健康服务 (+5%), while the largest declines were seen in KENVUE (-10%), REVVITY (-4%), and MOLINA HEALTHCARE (-3%) [4].

Group 1 - The top three companies with the highest short positions as of August 29 are ZTE Corporation (00763) at 16.47%, COSCO Shipping Holdings (01919) at 13.94%, and CATL (03750) at 13.88% [1][2] - The company with the largest increase in short positions is Ganfeng Lithium (01772), which rose by 2.85% to 12.46% [2][3] - The companies with the largest decrease in short positions include Hisense Home Appliances (00921), which decreased by 3.57% to 4.72%, and WuXi AppTec (02359), which decreased by 2.44% to 11.64% [3][4] Group 2 - The latest short position data shows that the top ten companies with the highest short ratios include China Ping An (02318) at 12.58% and Zijin Mining (02899) at 11.91% [2] - The companies with the most significant increases in short positions also include Huahong Semiconductor (01347) with an increase of 2.56% to 9.73% and Meitu (01357) with an increase of 1.80% to 4.85% [2] - The companies with the most significant decreases in short positions also include Weimob (02013) with a decrease of 1.66% to 9.40% and Linklogis Technology (09959) with a decrease of 1.43% to 2.76% [3][4]

致：香港交易及結算所有限公司 公司名稱: 四川科倫博泰生物醫藥股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 | 3. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | 於香港聯交所上市 (註1) | 否 | | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 非上市外資股 | | | FF301 第 1 頁 共 11 頁 v 1.1.1 FF301 | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | --- | --- | --- | --- | --- | --- | | 上月底結存 | | 4,642,190 RMB | | 1 RMB | 4,642,190 | | 增加 / 減少 (-) | | | | RMB | | | 本月底結存 | | 4,642,190 RMB | | 1 RMB | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) due to its considerable commercialization momentum and steady progress in its pipeline [5]. Core Views - The company reported a revenue of RMB 950 million for the first half of 2025, a year-on-year decrease of 31.3%, with a net loss attributable to shareholders of RMB 145 million [7]. - The company has made significant strides in commercialization, having obtained marketing approvals for several products and initiated their commercialization processes [7]. - The existing product indications are being expanded, and the potential pipeline is actively advancing, providing ample space for future growth [7]. - The company is expected to achieve total revenues of RMB 20.30 billion, RMB 32.77 billion, and RMB 53.63 billion for the years 2025 to 2027, respectively [7]. Financial Performance Summary - Revenue for 2023 is projected at RMB 1,540.49 million, with a year-on-year growth rate of 91.6%. For 2024, revenue is expected to be RMB 1,933.05 million, reflecting a growth rate of 25.5% [6]. - The net profit attributable to shareholders is forecasted to be a loss of RMB 560.39 million in 2025, with a significant recovery expected in 2027, reaching a profit of RMB 876.84 million [6]. - The company's cash and financial assets totaled RMB 4.528 billion as of June 30, 2025, an increase of 47.2% compared to the end of 2024 [7].

Group 1 - The biotechnology sector in the Hong Kong stock market experienced a significant decline, with several companies reporting substantial drops in their stock prices [1] - Notable declines include Clover Biopharmaceuticals, which fell by 14.13%, and Beigene, which dropped by 8.33% [2] - Other companies such as Innovent Biologics and WuXi Biologics also saw declines exceeding 5%, indicating a broader trend of negative performance in the sector [1][2] Group 2 - The following companies reported specific percentage declines: Clover Biopharmaceuticals (-14.13%), Beigene (-8.33%), and Innovent Biologics (-6.50%) [2] - Additional companies with notable declines include Kintor Pharmaceutical (-6.38%), CanSino Biologics (-5.98%), and Zai Lab (-5.50%) [2] - The overall trend suggests a challenging environment for biotechnology stocks in the Hong Kong market [1]

Summary of Key Points Core Viewpoint - The report highlights the top short-selling stocks in the Hong Kong market, indicating significant investor sentiment and potential market movements for these companies [1][2]. Short Selling Ratios - AIA Group Ltd (友邦保险-R) and JD Health (京东健康-R) both have a short-selling ratio of 100.00%, indicating complete short interest [1][2]. - JD Group (京东集团-SWR) follows with a short-selling ratio of 87.80% [1][2]. Short Selling Amounts - Alibaba Group (阿里巴巴-SW) leads in short-selling amount with 19.21 billion, followed by Tencent Holdings (腾讯控股) at 18.81 billion and Sanofi (三生制药) at 14.30 billion [1][2]. - Other notable companies include Meituan (美团-W) with 13.13 billion and BYD Company (比亚迪股份) with 12.05 billion [2]. Deviation Values - The top three stocks with the highest deviation values are Hong Kong Exchanges and Clearing (香港交易所-R) at 40.73%, AIA Group (友邦保险-R) at 37.99%, and JD Group (京东集团-SWR) at 36.59% [1][2]. - This deviation indicates a significant difference between current short-selling ratios and their historical averages [2]. Additional Insights - The report provides a detailed table of the top ten stocks by short-selling amounts, ratios, and deviation values, showcasing the current market sentiment towards these companies [2].

Core Viewpoint - The article highlights the significant style drift observed in the public fund "Baoying Modern Service Industry Mixed Fund," which has deviated from its stated investment theme, focusing heavily on the pharmaceutical and technology sectors instead of modern services [1][10]. Fund Performance and Holdings - As of the end of Q2 2025, the fund's top ten holdings are predominantly in the pharmaceutical and technology sectors, with a notable concentration in stocks like Kelun-Bio and Tencent Holdings, indicating a high industry concentration [1][2]. - The fund has shown high volatility and elasticity, achieving a return of 64.73% since the beginning of 2025 and 73.28% over the past year, ranking well among peers. However, it has experienced declines in previous years, with losses of 11.91% in 2021, 9.32% in 2022, and 3.7% in 2024, indicating issues with performance sustainability [2][9]. Managerial Strategy and Style Drift - The style drift has been evident since the current fund manager, Yao Yi, took over in January 2023, with the first quarterly report showing a complete focus on healthcare stocks, which accounted for over 50% of the net value [5][7]. - Despite achieving a total return of 46.78% and an annualized return of 15.85% under Yao Yi's management, the strategy has not aligned with the fund's original service-oriented theme, raising concerns about the appropriateness of the investment approach [7][9]. Regulatory and Market Implications - The fund's deviation from its contractual investment behavior raises compliance issues and may lead to unexpected risks for investors due to misinterpretation of the fund's theme [9][10]. - The fund's total size is 295 million yuan, with institutional investors holding 20.29%, indicating some level of external oversight, but individual investors remain the primary stakeholders [9].

Investment Rating - The report maintains an "OUTPERFORM" rating for Sichuan Kelun-Biotech with a target price of HK$519.20 [2][3]. Core Views - The company is expected to see robust growth driven by domestic commercialization and global collaborations, particularly in the ADC (Antibody-Drug Conjugate) sector [7][8]. - The drug Sac-TMT is anticipated to become a significant partner to Keytruda, with potential peak sales reaching USD 15-20 billion [8][13]. - The revenue forecasts for FY25-27 have been revised upwards, with expected revenues of RMB 20.6 billion, RMB 28.0 billion, and RMB 48.3 billion respectively [3][7]. Summary by Sections Financial Projections - Revenue for FY24 is projected at RMB 1.933 billion, increasing to RMB 2.056 billion in FY25, RMB 2.798 billion in FY26, and RMB 4.833 billion in FY27, reflecting growth rates of 25%, 6%, 36%, and 73% respectively [2][3]. - Net profit is expected to improve from a loss of RMB 267 million in FY24 to a profit of RMB 879 million by FY27 [2][3]. Product Pipeline and Market Position - The company has commercialized three products in China and has one product awaiting NDA approval, with over ten products in early clinical stages [7][8]. - The ADC platform is positioned as a leader in the domestic biopharmaceutical sector, with significant collaborations with Merck in the ADC field [7][8]. Clinical Development and Global Expansion - Sac-TMT has initiated 14 overseas clinical trials covering various cancers, with a potential patient population of 200,000 to 300,000 [8][20]. - The drug is expected to show strong sales growth in conjunction with Keytruda, particularly in lung cancer and breast cancer indications [8][13]. Competitive Landscape - Sac-TMT is positioned to become a best-in-class TROP2 ADC, with ongoing clinical trials expected to validate its efficacy against existing therapies [13][35]. - The report highlights the competitive advantages of Sac-TMT over other ADCs in the market, particularly in addressing unmet needs in NSCLC and breast cancer [24][35].

Core Viewpoints - The company's revenue for the first half of 2025 was 950 million yuan, a year-on-year decrease of 31.3%, primarily due to reduced milestone payments from licensing and collaboration agreements compared to the same period in 2024 [1][4] - The core product SKB264 generated revenue of 302 million yuan, with commercialization performance meeting market expectations [1][2] - Merck is actively advancing SKB264 with 14 global multi-center Phase III clinical studies [1][3] Financial Performance - The company reported a loss of 145 million yuan for the first half of 2025, a year-on-year decrease of 146.8%, while the adjusted loss was 69 million yuan, down 118.0% [1][5] - Drug sales revenue reached 310 million yuan, with a gross margin of 69.4% [1][5] - Cash and financial assets amounted to 4.528 billion yuan, a year-on-year increase of 47.2%, providing a solid foundation for long-term development [2][5] Product Development and Pipeline - SKB264 has achieved significant breakthroughs in breast cancer and lung cancer, becoming the first TROP2 ADC drug approved for EGFR mutation non-small cell lung cancer in the third-line treatment [2][3] - The company is pursuing multiple clinical studies covering high-incidence cancers, focusing on combination therapies and frontline treatments [2][3] - Early pipeline products are progressing well, with SKB315's Phase 1b clinical study ongoing and dual-specific ADC product SKB571's Phase II clinical trial set to launch in China [3][4] Future Catalysts - Key catalysts for the second half of 2025 include the expected approval of SKB264 for the 2L EGFR TKI-resistant NSCLC indication and the release of clinical data at academic conferences [4] - Other early ADC pipelines are anticipated to show preliminary clinical results [4] - The company has a robust pipeline with multiple products, including A166 and SKB315, expected to receive regulatory approvals in the near future [4][5]